BMO Capital Initiates Coverage on Pacira Pharmaceuticals Inc to Underperform

BMO Capital Initiates Coverage on Pacira Pharmaceuticals Inc(NASDAQ:PCRX). The shares have been rated Underperform. The rating by BMO Capital was issued on Jun 29, 2016.

In a different note, Mizuho Securities said it Initiates Coverage on Pacira Pharmaceuticals Inc, according to a research note issued on Apr 19, 2016. The shares have been rated ‘Buy’ by the firm.

Pacira Pharmaceuticals Inc (PCRX) shares turned negative on Fridays trading session with the shares closing down -0.25 points or -0.74% at a volume of 26,89,260. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $35.24. The peak price level was also seen at $35.24 while the days lowest was $32.16. Finally the shares closed at $33.48. The 52-week high of the shares is $80.25 while the 52-week low is $31.08. According to the latest information available, the market cap of the company is $1,244 M.

Pacira Pharmaceuticals Inc(PCRX) last announced its earnings results on May 2, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $65.47M. Analysts had an estimated revenue of $67.24M. Earnings per share were $0.14. Analysts had estimated an EPS of $0.08.

Several Insider Transactions has been reported to the SEC. On Jun 8, 2016, Lauren Bullaro Riker (Vice President, Finance) sold 938 shares at $47.67 per share price.Also, On Jun 8, 2016, Laura Brege (director) sold 1,000 shares at $46.95 per share price.On Jun 8, 2016, Kristen Marie Williams (CAO and General Counsel) sold 600 shares at $47.20 per share price, according to the Form-4 filing with the securities and exchange commission.

Pacira Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the development commercialization and manufacture of pharmaceutical products based on its DepoFoam drug delivery technology primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the company’s lead product candidate EXPAREL a liposome injection of bupivacaine an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL DepoFoam is also the basis for its other commercial product DepoCyt(e) which the Company manufactures for its commercial partners as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Pacira Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pacira Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.